RTA Laboratuvarlari Biyolojik - Asset Resilience Ratio

Latest as of June 2025: 0.21%

RTA Laboratuvarlari Biyolojik (RTALB) has an Asset Resilience Ratio of 0.21% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

TL4.69 Million

≈ $105.07K USD Cash + Short-term Investments

Total Assets

TL2.23 Billion

≈ $49.90 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how RTA Laboratuvarlari Biyolojik's Asset Resilience Ratio has changed over time. Check asset allocation strategy of RTA Laboratuvarlari Biyolojik to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down RTA Laboratuvarlari Biyolojik's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RTALB market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	TL0.00	0%
Short-term Investments	TL4.69 Million	0.21%
Total Liquid Assets	TL4.69 Million	0.21%

Asset Resilience Insights

Limited Liquidity: RTA Laboratuvarlari Biyolojik maintains only 0.21% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

RTA Laboratuvarlari Biyolojik Industry Peers by Asset Resilience Ratio

Compare RTA Laboratuvarlari Biyolojik's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%

Annual Asset Resilience Ratio for RTA Laboratuvarlari Biyolojik (2016–2024)

The table below shows the annual Asset Resilience Ratio data for RTA Laboratuvarlari Biyolojik.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.23%	TL4.47 Million ≈ $100.14K	TL1.92 Billion ≈ $43.03 Million	-5.38pp
2023-12-31	5.61%	TL101.20 Million ≈ $2.27 Million	TL1.80 Billion ≈ $40.42 Million	-10.34pp
2022-12-31	15.95%	TL118.08 Million ≈ $2.64 Million	TL740.21 Million ≈ $16.58 Million	+14.89pp
2021-12-31	1.06%	TL5.86 Million ≈ $131.31K	TL552.40 Million ≈ $12.37 Million	+0.70pp
2020-12-31	0.36%	TL916.80K ≈ $20.53K	TL256.52 Million ≈ $5.75 Million	+0.28pp
2018-12-31	0.08%	TL51.38K ≈ $1.15K	TL66.05 Million ≈ $1.48 Million	-2.61pp
2017-12-31	2.69%	TL1.70 Million ≈ $38.01K	TL63.09 Million ≈ $1.41 Million	-0.16pp
2016-12-31	2.85%	TL1.73 Million ≈ $38.85K	TL60.89 Million ≈ $1.36 Million	--

pp = percentage points

About RTA Laboratuvarlari Biyolojik

IS:RTALB Turkey Biotechnology

Market Cap

$33.37 Million

TL1.49 Billion TRY

Market Cap Rank

#23404 Global

#401 in Turkey

Share Price

TL2.98

Change (1 day)

-1.65%

52-Week Range

TL2.98 - TL4.71

All Time High

TL29.60